Biomarker ID | 683 |
PMID | 21741162 |
Year | 2011 |
Biomarker | thrombospondin 1 (THBS1) + C-Reactive Prostien (CRP) + poliovirus receptor-related 1 (PVRL1) + memembrane metallo endopeptidase (MME) +ephrin- A5 (EFNA5) |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | NA |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include(THBS1):- Integrin cell surface interactions, Beta-3 integrin cell surface interactions, Malaria, Senescence and autophagy, TGF-beta regulation of skeletal system development Pathways Include(CRP):-Vitamin B12 metabolism,Selenium pathway, Folate metabolism,Interleukin-6 signaling pathway,Complement cascade Pathways Include (NECTIN1):- Cell junction organization, Adherens junction, Cell adhesion molecules (CAMs), Herpes simplex virus 1 infection, PAK Pathway |
Experiment | Overall Survival Vs No Survival (24 months) |
Type of Biomarker | Prognostic |
Cohort | 57 patients with prostate cancer were included in the study. At the time of the analysis, 65% of patients had died (n = 37); of these, 89% (n = 33) died from mCRPC. |
Senstivity | NA |
Specificity | NA |
AUC | 0.943 (95% CI: 0.894–0.985) |
Accuracy | 94% |
Level Of Significance | NA |
Method Used | ELISA + Mass Spectrometry |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | THBS1, CRP, NECTIN1, MME, EFNA5 |